Functional antibodies to the O-acetylated pneumococcal serotype 15B capsular polysaccharide have low cross-reactivities with serotype 15C

Clinical and Vaccine Immunology

Volumn 14, Issue 9, 2007, Pages 1223-1227

  Rajam, Gowrisankar ^a   Carlone, George M ^a   Romero Steiner, Sandra ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ACETYLATION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; HUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; VACCINATION;

ABSORPTION; ACETYLATION; ANTIBODIES, BACTERIAL; ANTIGEN-ANTIBODY COMPLEX; CROSS REACTIONS; HUMANS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 34948859082     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00184-07     Document Type: Article

References (24)

1. Barker, S. A., M. Stacey, and J. M. Williams. 1960. New data about the structure of antigenic polysaccharides of pneumococcus. Bull. Soc. Chim. Biol. 42:1611-1618.
2. Berry, D. S., F. Lynn, C. H. Lee, C. E. Frasch, and M. C. Bash. 2002. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. 70: 3707-3713.
3. Butler, J. C., R. F. Breiman, J. F. Campbell, H. B. Lipman, C. V. Broome, and R. R. Facklam. 1993. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 270:1826-1831.
4. Byington, C. L., K. Korgenski, J. Daly, K. Ampofo, A. Pavia, and E. O. Mason. 2006. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr. Infect. Dis. J. 25:250-254.
5. Cutts, F. T., S. M. Zaman, G. Enwere, S. Jaffar, O. S. Levine, J. B. Okoko, C. Oluwalana, A. Vaughan, S. K. Obaro, A. Leach, K. P. McAdam, E. Biney, M. Saaka, U. Onwuchekwa, F. Yallop, N. F. Pierce, B. M. Greenwood, and R. A. Adegbola. 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365:1139-1146.
6. Ellerbroek, P. M., D. J. Lefeber, R. van Veghel, J. Scharringa, E. Brouwer, G. J. Gerwig, G. Janbon, A. I. Hoepelman, and F. E. Coenjaerts. 2004. O-acetylation of cryptococcal capsular glucuronoxylomannan is essential for interference with neutrophil migration. J. Immunol. 173:7513-7520.
7. Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, R. Kohberger, G. Siber, and P. H. Makela. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
8. Fusco, P. C., E. K. Farley, C. H. Huang, S. Moore, and F. Michon. 2007. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin. Vaccine Immunol. 14:577-584.
9. Gertz, R. E., Jr., M. C. McEllistrem, D. J. Boxrud, Z. Li, V. Sakota, T. A. Thompson, R. R. Facklam, J. M. Besser, L. H. Harrison, C. G. Whitney, and B. Beall. 2003. Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J. Clin. Microbiol. 41:4194-4216.
10. Giardina, P. C., E. Longworth, R. E. Evans-Johnson, M. L. Bessette, H. Zhang, R. Borrow, D. Madore, and P. Fernsten. 2005. Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide. Clin. Diagn. Lab. Immunol. 12:586-592.
11. Janssen, P. E., B. Lindberg, U. Lindquist, and J. Ljungberg. 1987. Structural studies of the capsular polysaccharide from Streptococcus pneumoniae types 15B and 15C. Carbohydr. Res. 162:111-116.
12. Kaplan, S. L., E. O. Mason, Jr., E. R. Wald, G. E. Schutze, J. S. Bradley, T. Q. Tan, J. A. Hoffman, L. B. Givner, R. Yogev, and W. J. Barson. 2004. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113:443-449.
13. Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. Mbelle, and N. Pierce. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348.
14. Neufeld, F. 1902. Uber die agglutina der Pneumokokken und uber die theorien der Agglutination. Z. Hyg. Infeckt-Kr. 40:54-72.
15. Ortqvist, A. 2001. Pneumococcal vaccination: current and future issues. Eur. Respir. J. 18:184-195.
16. Pai, R., M. R. Moore, T. Pilishvili, R. E. Gertz, C. G. Whitney, and B. Beall. 2005. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192:1988-1995.
17. Park, I., D. G. Pritchard, R. Cartee, A. Brandao, M. C. Brandileone, and M. H. Nahm. 2007. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J. Clin. Microbiol. 45:1225-1233.
18. Robbins, J. J. B., R. R. Austrian, C. C. J. Lee, S. S. C. Rastogi, G. G. Schiffman, J. J. Henrichsen, P. P. H. Mäkelä, C. C. V. Broome, R. R. R. Facklam, and R. R. H. Tiesjema. 1983. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148:1136- 1159.
19. Romero-Steiner, S., C. E. Frasch, G. Carlone, R. A. Fleck, D. Goldblatt, and M. H. Nahm. 2006. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin. Vaccine Immunol. 13:165-169.
20. Romero-Steiner, S., D. Libutti, L. B. Pais, J. Dykes, P. Anderson, J. C. Whitin, H. L. Keyserling, and G. M. Carlone. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 4:415-422.
21. Saeland, E., H. Jakobsen, G. Ingolfsdottir, S. T. Sigurdardottir, and I. Jonsdottir. 2001. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J. Infect. Dis. 183:253-260.
22. Singleton, R. J., T. W. Hennessy, L. R. Bulkow, L. L. Hammitt, T. Zulz, D. A. Hurlburt, J. C. Butler, K. Rudolph, and A. Parkinson. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784-1792.
23. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, and A. Schuchat. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.
24. Yu, X., B. Gray, S. Chang, J. I. Ward, K. M. Edwards, and M. H. Nahm. 1999. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J. Infect. Dis. 180:1569-1576.